Tilray Inc. (Tilray) recently announced it has signed a partnership with Novartis AG (Novartis) subsidiary Sandoz to develop and globally distribute medical cannabis. The move is possible thanks to Tilray building upon its existing alliance with Sandoz Canada Inc., one of the fastest-growing pharmaceutical companies in the Canadian market.
Under the partnership, the organizations plan to commercialize Tilray’s non-smokable medical cannabis products, as well as co-brand some of its products, develop new products, and help educate clinical professionals about cannabis. Tilray leadership cited Sandoz’s focus on consumers, reliable supply chain, well-established sales force, and global distribution network as reasons for its interest in partnering with the organization.
Tilray is a Canadian pharmaceutical and cannabis company, incorporated in the United States, with primary operations headquartered in Nanaimo, British Columbia. Novartis is a global health care company based in Switzerland that provides solutions to address the evolving needs of consumers worldwide.
This was reported by Bloomberg on December 18, 2018.
Contact Information: Tilray Inc., 1100 Maughan Road Nanaimo, British Columbia V9X 1J2, Canada; (844) 845-7291; Website: www.tilray.com
Contact Information: Sandoz Pharmaceuticals AG, Surrstoffi, 14, CH-6343 Rotkreuz, Switzerland; US – (862) 778 2100, CH – +41 41 763 7411; Website: www.novartis.com